The safety and efficacy of gemcitabine and cisplatin (GP)‐based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta‐analysis-Reference-Cited by-同舟云学术

The safety and efficacy of gemcitabine and cisplatin (GP)‐based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta‐analysis

Published:2021-07-14 Issue: Volume: Page:
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

Tang Min^ORCID,Jia Zhongxiong,Zhang Ju

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Otorhinolaryngology

Link

https://link.springer.com/content/pdf/10.1007/s00405-021-06940-0.pdf

Reference39 articles.

1. Chen YP, Chan ATC, Le QT et al (2019) Nasopharyngeal carcinoma. Lancet (London, England) 394(10192):64–80

2. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

3. Ferlay J, Colombet M, Soerjomataram I et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387

4. Chan AT, Teo PM, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13(7):1007–1015

5. Guan H, He Y, Wei Z et al (2020) Assessment of induction chemotherapy regimen TPF vs GP followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective cohort study of 160 patients. Clin Otolaryngol 45:274–279

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study;Translational Oncology;2024-10

2. Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma;European Archives of Oto-Rhino-Laryngology;2022-12-27